A real-world comparison of non-TNF targeted biologics has shown rituximab and tocilizumab are more effective than abatacept in patients with refractory rheumatoid arthritis (RA). The data was from more than 3,000 RA patients enrolled in French rheumatology registries, previously treated with TNF inhibitors and followed for at least two years after initiation on one of ...
Non-TNF biologics’ effectiveness compared in ‘real world’ RA study
By Mardi Chapman
5 Feb 2019